IONS Ionis Pharmaceuticals, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
20:46
Sep 04
Sep 04
The author expresses confusion about unexplained cardiovascular sector movements involving.
The author expresses confusion about unexplained cardiovascular sector movements involving Novartis and Ionis, but offers no directional position or thesis.
20:44
Sep 04
Sep 04
The author expresses pain over NVS and IONS losses and sarcastically tells Vas to get.
The author expresses pain over NVS and IONS losses and sarcastically tells Vas to get the checkbook out, implying a need for capital but no explicit position or forward call.
09:58
Aug 03
Aug 03
A news wire reports a broad list of price target increases from multiple banks across dozens.
A news wire reports a broad list of price target increases from multiple banks across dozens of stocks, with no explicit directional calls or personal market views expressed.
12:30
Jul 29
Jul 29
Biogen made a milestone payment to Ionis for its partnered SMA program, salinersin.
HIGH
13:57
Jul 10
Jul 10
The author makes a nostalgic reference to Ionis Pharmaceuticals as a past "terror cell" without.
The author makes a nostalgic reference to Ionis Pharmaceuticals as a past "terror cell" without expressing any current position or trade idea.
LOW
12:13
Jul 09
Jul 09
Premarket movers report shows mixed Mag 7 stocks.
Premarket movers report shows mixed Mag 7 stocks, with notable gains for CECO on JPMorgan initiation, ALNY and BBIO on rival drug trial failure, and SMPL on earnings beat, while IBM, IONS, LEVI, MAT, and CRM decline on various negative catalysts.
08:04
Jun 30
Jun 30
The tweet reports a list of stocks receiving analyst upgrades but does not state the author's.
The tweet reports a list of stocks receiving analyst upgrades but does not state the author's own position, making it a factual research summary rather than a trade idea.
LOW
21:52
Mar 02
Mar 02
Jeffrey mentions that for his son's disease (CTD), pharmaceutical companies are looking at "ASO therapy" (Antisense Oligonucleotide) and "prodrugs" to bypass the blood-brain barrier. Ionis (IONS) is the market leader in RNA-targeted ASO therapies, and Ultragenyx (RARE) specializes in rare genetic diseases and metabolic disorders. When a specific modality like ASO is highlighted as the solution for neurological transport issues, it validates the broader technology platforms of these specialized firms. Watch these tickers as proxies for advancements in ASO and rare disease drug delivery. Clinical trial failures are common in rare disease; "science is slow" (as stated by the guest).
About IONS Analyst Coverage
Buzzberg tracks IONS (Ionis Pharmaceuticals, Inc. Common Stock) across 7 sources. 0 bullish vs 0 bearish calls from 7 analysts. Sentiment: evenly split. 8 total trade ideas tracked. Past 7 days: 2 watch. Latest voices: A May MD, seedy19tron, DeItaone.